Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.8380
-0.0410 (-4.66%)
At close: Aug 13, 2025, 4:00 PM
0.8700
+0.0320 (3.82%)
Pre-market: Aug 14, 2025, 8:58 AM EDT
Company Description
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia.
Nexalin Technology, Inc. is headquartered in Houston, Texas.
Nexalin Technology, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Sep 16, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark White |
Contact Details
Address: 1776 Yorktown, Suite 550 Houston, Texas 77056 United States | |
| Phone | 832 260 0222 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B201 |
| ISIN Number | US65345B2016 |
| Employer ID | 27-5566468 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Carolyn Shelton | Executive Vice President of Clinical, Quality and Regulatory Affairs and Chief Operating Officer |
| Dr. David Owens M.D. | Chief Medical Officer, Member of Scientific Advisory Board and Director |
| Marilyn Elson | Controller |
| John Patrick Claude | Co-Founder and Director of Engineering and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jun 17, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 9, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| May 6, 2025 | 424B4 | Prospectus |
| May 5, 2025 | 424B5 | Filing |